keytruda
Keytruda continues success with new Phase 3 data in adjuvant melanoma
April 16, 2018Research and Development, Sales and Marketing Cancer, MSD, keytruda, melanoma, pharma, skinc cancer
MSD has revealed new efficacy data for Keytruda (permbrolizumab) as an adjuvant therapy in the treatment of resected, high-risk stage …
Keytruda scores big as a first-line monotherapy in NSCLC patients with any level of PD-L1 expression
April 10, 2018Manufacturing and Production, Research and Development Cancer, MSD, NSCLC, keytruda, lung cancer, pharma
Closely following the news that Keytruda (pembrolizumab) had failed in the treatment of unresectable or metastatic melanoma as a combination …
Keytruda combo fails at Phase 3 in metastatic melanoma
April 9, 2018Research and Development, Sales and Marketing Incyte, MSD, keytruda, pharma, trial failure
Shares in biopharma firm Incyte were sent reeling by as much as 20% when the company announced that the results …
NICE recommends Keytruda via CDF as first and only urothelial carcinoma immunotherapy
March 16, 2018Medical Communications, Sales and Marketing MSD, NICE, immunotherapy, keytruda, pharma
UK drugs watchdog NICE has published its finance guidance recommending the use of MSD’s Keytruda (pembrolizumab) on the NHS through …
Eisai and MSD team up to combine Lenvima and Keytruda in cancer
March 8, 2018Sales and Marketing Cancer, Eisai, Kidney cancer, Lenvima, MSD, Merck, keytruda, pharma
Pharma heavyweights MSD (Merck) and Eisai have announced they are to join forces to develop and commercialise the latter’s tyrosine …
Japan saves record $12.2bn in 2017 through greater generic use
March 7, 2018Research and Development, Sales and Marketing Japan, generics, keytruda, opdivo, pharma
Through a concerted shift from branded drugs to generic equivalents as a means to lower prescription costs, Japan is estimated …
MSD poised to acquire viral immuno-oncology firm Viralytics for $394m
February 21, 2018Research and Development, Sales and Marketing Cancer, MSD, Merck, Viralytics, acquisition, keytruda, oncology, pharma
MSD, known as Merck in the US, has announced it is to buy Australian viral immuno-oncology firm Viralytics for $394 …
MSD’s interim Keytruda combo data spooks Roche and BMS
January 16, 2018Research and Development MSD, Merck, biotech, drugs, keytruda, pharma, pharmaceutical
When PD-1/L1 treatments first came on the market, there was a race to snaffle as many indications as possible for …
Keytruda falls hard at gastric cancer hurdle
December 18, 2017Research and Development, Sales and Marketing MSD, biotech, drugs, keytruda, pharma, pharmaceutical
There was a time when PD-1/L1 immunotherapy treatments could do no wrong, blasting through indication after indication. However, the limits …
MSD withdraws European application of Keytruda combo in lung cancer
October 30, 2017Sales and Marketing EMA, MSD, keytruda
MSD has been forced to withdraw its EU marketing application for Keytruda (pembrolizumab) in combination with pemetrexed and carboplatin as …
MSD plays catch up with €464m deal for fledgling biotech
September 7, 2017Sales and Marketing Bristol-Myers Squibb, MSD, biotech, drugs, keytruda, pharma, pharmaceutical
MSD has announced that it will acquire Rigontec, a three-year old German biotech, in a deal worth an initial €115 …
MSD’s Keytruda hits rare snag, floundering in confirmatory trial
July 25, 2017Manufacturing and Production, Sales and Marketing MSD, Merck, biotech, drugs, keytruda, pharma, pharmaceutical
Since the PD-1/PD-L1 immunotherapies have hit the market, they have revolutionised cancer care for many patients yet, with the science …
FDA shutters MSD’s Keytruda combination trials in myeloma
July 6, 2017Medical Communications, Research and Development MSD, immunotherapy, keytruda, pd-1
Following on from the news last month that enrolment for Keytruda being used alongside Celgene’s Imnovid and Revlimid would have …
LifeArc rebrands and sets up £500m research fund
June 15, 2017Medical Communications, Research and Development, Sales and Marketing LifeArc, MRC Technology, keytruda
The UK medical research charity formerly known as MRC Technology has rebranded to be known as LifeArc. At the same …
MSD receives first FDA approval based on specific genetic feature
May 24, 2017Research and Development, Sales and Marketing MSD, Precision Medicine, biomarker, keytruda
In a historic first, MSD (known as Merck in North America) has received approval for its immunotherapy treatment Keytruda in …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
